519 related articles for article (PubMed ID: 35440464)
1. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L;
BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464
[TBL] [Abstract][Full Text] [Related]
2. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Xu J; Kato K; Raymond E; Hubner RA; Shu Y; Pan Y; Park SR; Ping L; Jiang Y; Zhang J; Wu X; Yao Y; Shen L; Kojima T; Gotovkin E; Ishihara R; Wyrwicz L; Van Cutsem E; Jimenez-Fonseca P; Lin CY; Wang L; Shi J; Li L; Yoon HH
Lancet Oncol; 2023 May; 24(5):483-495. PubMed ID: 37080222
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
4. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S; Wu L; Jian H; Chen Y; Wang Q; Fang J; Wang Z; Hu Y; Sun M; Han L; Miao L; Ding C; Cui J; Li B; Pan Y; Li X; Ye F; Liu A; Wang K; Cang S; Zhou H; Sun X; Ferry D; Lin Y; Wang S; Zhang W; Zhang C
Lancet Oncol; 2022 Sep; 23(9):1167-1179. PubMed ID: 35908558
[TBL] [Abstract][Full Text] [Related]
5. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S; Wu L; Jian H; Cheng Y; Wang Q; Fang J; Wang Z; Hu Y; Han L; Sun M; Miao L; Ding C; Cui J; Wang K; Li B; Li X; Ye F; Liu A; Pan Y; Cang S; Zhou H; Sun X; Shen Y; Wang S; Zhang W; He Y
Lancet Respir Med; 2023 Jul; 11(7):624-636. PubMed ID: 37156249
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
[TBL] [Abstract][Full Text] [Related]
8. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J; Jiang H; Pan Y; Gu K; Cang S; Han L; Shu Y; Li J; Zhao J; Pan H; Luo S; Qin Y; Guo Q; Bai Y; Ling Y; Yang J; Yan Z; Yang L; Tang Y; He Y; Zhang L; Liang X; Niu Z; Zhang J; Mao Y; Guo Y; Peng B; Li Z; Liu Y; Wang Y; Zhou H;
JAMA; 2023 Dec; 330(21):2064-2074. PubMed ID: 38051328
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
12. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
13. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Zhou C; Wu L; Fan Y; Wang Z; Liu L; Chen G; Zhang L; Huang D; Cang S; Yang Z; Zhou J; Zhou C; Li B; Li J; Fan M; Cui J; Li Y; Zhao H; Fang J; Xue J; Hu C; Sun P; Du Y; Zhou H; Wang S; Zhang W
J Thorac Oncol; 2021 Sep; 16(9):1501-1511. PubMed ID: 34048947
[TBL] [Abstract][Full Text] [Related]
14. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
Song Y; Zhang B; Xin D; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Li J; Wang Q; Zhu J; Huang J;
Nat Med; 2023 Feb; 29(2):473-482. PubMed ID: 36732627
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
16. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
18. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.
Kojima T; Hara H; Tsuji A; Yasui H; Muro K; Satoh T; Ogata T; Ishihara R; Goto M; Baba H; Nishina T; Han S; Sakata T; Yatsuzuka N; Doi T; Kato K
Esophagus; 2022 Oct; 19(4):683-692. PubMed ID: 35668304
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
